{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:54:08Z","timestamp":1792011248540,"version":"4.4.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cardfail.2026.08.025","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:09:28Z","timestamp":1789024168000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["When the Gradient Falls, Do Symptoms Follow? Understanding the impact of Myosin Inhibitors on Patient Reported Outcomes"],"prefix":"10.1016","author":[{"given":"MEAGHAN","family":"O\u2019HARA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTOPHER","family":"SCIAMANNA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GENE H.","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NIKHIL","family":"NARANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.08.025_bib0001","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.amjcard.2017.08.048","article-title":"Interaction of adverse disease related pathways in hypertrophic cardiomyopathy","volume":"120","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0002","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ehjqcco\/qcae092","article-title":"Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study","volume":"11","author":"Schoonvelde","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0003","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0004","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1053\/euhj.2002.3285","article-title":"Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes","volume":"23","author":"Firoozi","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.041328","article-title":"Effects of alcohol septal ablation on exercise hemodynamics, symptoms, and quality of life in obstructive hypertrophic cardiomyopathy","volume":"14","author":"Dybro","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0006","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0007","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2026.03.036","article-title":"Impact of mavacamten on disease-related symptoms in patients with obstructive hypertrophic cardiomyopathy: HCMSQ Outcomes in EXPLORER-HCM","author":"Saberi","year":"2026","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102587","article-title":"Minimally Important Kansas City Cardiomyopathy Questionnaire Changes Across the Spectrum of Heart Failure Severity","volume":"13","author":"Spertus","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102679","article-title":"Recalibrating Our Understanding of Meaningful Health Status Change in Heart Failure","volume":"13","author":"Sandhu","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0011","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pcad.2023.08.007","article-title":"Owens AT. Patient-reported outcomes in clinical studies of patients with hypertrophic cardiomyopathy","volume":"80","author":"Reza","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cardfail.2026.08.025_bib0012","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s41669-022-00340-8","article-title":"Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial","volume":"6","author":"Reaney","year":"2022","journal-title":"Pharmacoecon Open"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426005294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426005294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:41:53Z","timestamp":1792010513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426005294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":12,"alternative-id":["S1071916426005294"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.08.025","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When the Gradient Falls, Do Symptoms Follow? Understanding the impact of Myosin Inhibitors on Patient Reported Outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.03.036","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}